
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA – Free Report) – Diamond Equity lifted their FY2026 earnings per share (EPS) estimates for shares of MAIA Biotechnology in a report issued on Thursday, November 12th. Diamond Equity analyst H. Diamond now expects that the company will post earnings per share of ($0.48) for the year, up from their previous estimate of ($0.54). The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($0.54) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.44) EPS.
MAIA Biotechnology (NYSEAMERICAN:MAIA – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01.
MAIA Biotechnology Price Performance
MAIA Biotechnology stock opened at $1.01 on Tuesday. MAIA Biotechnology has a one year low of $0.87 and a one year high of $3.19. The business’s fifty day moving average is $1.18 and its 200 day moving average is $1.40. The stock has a market capitalization of $62.37 million, a PE ratio of -2.15 and a beta of 0.28.
Insider Transactions at MAIA Biotechnology
In related news, Director Ramiro Guerrero bought 78,239 shares of the stock in a transaction on Thursday, August 27th. The shares were acquired at an average price of $1.39 per share, for a total transaction of $108,752.21. Following the purchase, the director owned 689,081 shares of the company’s stock, valued at approximately $957,822.59. The trade was a 12.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Vlad Vitoc purchased 73,000 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were bought at an average cost of $1.37 per share, for a total transaction of $100,010.00. Following the acquisition, the chief executive officer owned 1,049,121 shares in the company, valued at approximately $1,437,295.77. The trade was a 7.48% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders acquired 258,078 shares of company stock valued at $352,426. 19.81% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MAIA. Centric Wealth Management purchased a new stake in MAIA Biotechnology during the 2nd quarter valued at $1,107,000. Cable Car Capital LP bought a new position in shares of MAIA Biotechnology during the 2nd quarter valued at $741,000. BlackRock Inc. purchased a new position in shares of MAIA Biotechnology in the 2nd quarter worth $580,000. Marshall Wace LLP purchased a new position in shares of MAIA Biotechnology in the 3rd quarter worth $100,000. Finally, Empowered Funds LLC purchased a new position in shares of MAIA Biotechnology in the 3rd quarter worth $88,000. Institutional investors own 5.65% of the company’s stock.
About MAIA Biotechnology
MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Its research centers on therapies that target telomeres, protective structures at the ends of chromosomes that can help cancer cells continue to divide. The company’s lead drug candidate, ateganosine (also known as THIO or 6-thio-dG), is designed to disrupt telomeres in cancer cells and promote their death. MAIA has evaluated ateganosine in clinical research, including studies involving patients with advanced non-small cell lung cancer and treatment in combination with the immunotherapy cemiplimab.
See Also
- Five stocks we like better than MAIA Biotechnology
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for MAIA Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAIA Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
